Scientists have hailed ‘encouraging results’ for treatment of acute leukaemias that have KMT2A rearrangements or NPM1 mutations.
A phase 1 trial of the drug revumenib has showed, among 60 patients with advanced acute leukaemias with KMT2A rearrang...
1 year ago
The malfunctioning behaviour of an immune cell could be linked to specific symptoms of long COVID, opening the way to treatments, British researchers have reported.
Normally functioning monocytes travel through the blood to the lungs, where they s...
1 year ago
